Quality of life and decision regret in patients with late‐hypothyroidism after radioiodine treatment for Graves' disease

Author:

Li Yue1ORCID,Yang Tianyu1,Ju Linjun1,Feng Yuyue1,Chen Zheng1,Xiang Xing1,Zhu Tao1,Pang Hua1,Wang Zhengjie1

Affiliation:

1. Department of Nuclear Medicine The First Affiliated Hospital of Chongqing Medical University Chongqing China

Abstract

AbstractObjectivePatients with Graves' disease often engage in shared decision‐making to select an individualised treatment regimen from multiple options. Radioactive iodine (RAI) is one of the treatment choices for their condition, aims to improve quality of life and well‐being. Likewise, dissatisfaction with treatment outcomes can result in decision regret. We employed validated questionnaires to assess the prospective quality of life, decision regret and relative factors involved in decision‐making of patients with late hypothyroidism after RAI therapy.MethodsA questionnaire survey was conducted among patients in hypothyroidism status for more than 1 year after RAI therapy. Disease‐specific and generic QoL were assessed using the short form of thyroid‐related patient‐reported outcome (ThyPRO‐39) questionnaire. Patient satisfaction regarding their decision to undergo RAI was assessed using the Decision Regret Scale (DRS) and patients were asked about the importance of relative factors in decision‐making.ResultsOf 254 patients who responded to the survey, the mean age of patients was 45.3 years (range: 18–78 years) and the median time from RAI therapy to survey was 4 years (range: 1–30 years). Patients' median and mean DRS score were 34.4 and 38.8 (range: 0–100), respectively. A total of 100 (39.4%) patients express absent‐to‐mild regret (score: 0–25), 154 (60.6%) patients express moderate‐to‐severe regret (score: >25). The mean score of the absent‐to‐mild regret group were significantly higher than those of the moderate‐to‐severe regret group on most ThyPRO‐39 scales. A statistically significant positive correlation was observed between DRS score and most ThyPRO‐39 scale score. There was a significant positive association between higher DRS score and longer time intervals after RAI treatment, a brief duration of hyperthyroidism, and the significance of long‐time outpatient follow‐up. More decision regret was negatively associated Iodine‐free diet, ineffectiveness of ATD, fear of surgery.ConclusionImpairment of quality of life was positively correlated with decision regret in patients with late‐hypothyroidism after radioiodine therapy. Patients with insufficient information support before decision‐making are more likely to have higher decision regret after treatment. Our findings suggest that health providers should fully communicate with patients and provide information support in multiple dimensions during the shared‐decision‐making process.

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Reference33 articles.

1. Hyperthyroidism: diagnosis and treatment;Kravets I;Am Fam Physician,2016

2. Treatment decision satisfaction and regret after focal HIFU for localized prostate cancer

3. Clinical guidelines for 131I treatment of Graves’ hyperthyroidism (2013 edition);Ning YJ;Labeled Immunoassays & Clin Med,2014

4. Impaired decision making under risky conditions in the acute phase of Graves’ thyroitoxicosis

5. Regret in cancer-related decisions.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3